No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. 2000

A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
Department of Psychological Medicine, Institute of Psychiatry, London, UK.

The adrenergic system plays an important role in psychiatric disorders such as depression and schizophrenia. Antagonism of the adrenergic receptor subtypes alpha1A and alpha2A has been found to have an antipsychotic effect. Genetic mutations in these receptors could be related to the alterations in the adrenergic system observed in psychiatric patients and to failure to respond to drug antagonism. We have studied one polymorphism in the alpha1A-adrenergic receptor (Arg492Cys) and two polymorphisms in the promoter region of the alpha2A-adrenergic receptor (-1291-C/G and -261-G/A) in a sample of clozapine-treated schizophrenic patients and controls. No clear differences were observed between the different groups suggesting that these polymorphisms did not play an important role in the aetiology of the disorder or in determining antipsychotic response.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D018340 Receptors, Adrenergic, alpha-1 A subclass of alpha-adrenergic receptors that mediate contraction of SMOOTH MUSCLE in a variety of tissues such as ARTERIOLES; VEINS; and the UTERUS. They are usually found on postsynaptic membranes and signal through GQ-G11 G-PROTEINS. Adrenergic alpha-1 Receptors,Receptors, alpha-1 Adrenergic,alpha-1 Adrenergic Receptors,Adrenergic Receptor, alpha-1,Adrenergic alpha-1A Receptors,Adrenergic alpha-1B Receptors,Adrenergic alpha-1D Receptors,Receptor, Adrenergic, alpha-1,Receptor, Adrenergic, alpha-1A,Receptor, Adrenergic, alpha-1B,Receptor, Adrenergic, alpha-1D,Receptors, Adrenergic, alpha-1A,Receptors, Adrenergic, alpha-1B,Receptors, Adrenergic, alpha-1D,alpha 1 Adrenergic Receptor,alpha-1A Adrenergic Receptor,alpha-1B Adrenergic Receptor,alpha-1C Adrenergic Receptor,alpha-1D Adrenergic Receptor,Adrenergic Receptor, alpha 1,Adrenergic Receptor, alpha-1A,Adrenergic Receptor, alpha-1B,Adrenergic Receptor, alpha-1C,Adrenergic Receptor, alpha-1D,Adrenergic Receptors, alpha-1,Adrenergic alpha 1 Receptors,Adrenergic alpha 1A Receptors,Adrenergic alpha 1B Receptors,Adrenergic alpha 1D Receptors,Receptor, alpha-1 Adrenergic,Receptor, alpha-1A Adrenergic,Receptor, alpha-1B Adrenergic,Receptor, alpha-1C Adrenergic,Receptor, alpha-1D Adrenergic,Receptors, Adrenergic alpha-1,Receptors, Adrenergic alpha-1A,Receptors, Adrenergic alpha-1B,Receptors, Adrenergic alpha-1D,Receptors, alpha 1 Adrenergic,alpha 1 Adrenergic Receptors,alpha 1A Adrenergic Receptor,alpha 1B Adrenergic Receptor,alpha 1C Adrenergic Receptor,alpha 1D Adrenergic Receptor,alpha-1 Adrenergic Receptor,alpha-1 Receptors, Adrenergic,alpha-1A Receptors, Adrenergic,alpha-1B Receptors, Adrenergic,alpha-1D Receptors, Adrenergic
D018341 Receptors, Adrenergic, alpha-2 A subclass of alpha-adrenergic receptors found on both presynaptic and postsynaptic membranes where they signal through Gi-Go G-PROTEINS. While postsynaptic alpha-2 receptors play a traditional role in mediating the effects of ADRENERGIC AGONISTS, the subset of alpha-2 receptors found on presynaptic membranes signal the feedback inhibition of NEUROTRANSMITTER release. Adrenergic alpha-2 Receptors,Receptors, alpha-2 Adrenergic,alpha-2 Adrenergic Receptors,Adrenergic Receptor alpha(2C),Adrenergic Receptor alpha(2d),Adrenergic Receptor alpha-2C,Adrenergic Receptor alpha-2b,Adrenergic Receptor, alpha-2,Adrenergic alpha-2A Receptors,Adrenergic alpha-2B Receptors,Adrenergic alpha-2C Receptors,Adrenergic alpha-2D Receptors,Receptor, Adrenergic, alpha-2,Receptor, Adrenergic, alpha-2A,Receptor, Adrenergic, alpha-2B,Receptor, Adrenergic, alpha-2C,Receptor, Adrenergic, alpha-2D,Receptors, Adrenergic, alpha-2A,Receptors, Adrenergic, alpha-2B,Receptors, Adrenergic, alpha-2D,alpha 2 Adrenergic Receptors,alpha-2A Adrenergic Receptor,alpha-2B Adrenergic Receptor,alpha-2C Adrenergic Receptor,alpha-2D Adrenergic Receptor,Adrenergic Receptor alpha 2C,Adrenergic Receptor alpha 2b,Adrenergic Receptor, alpha 2,Adrenergic Receptor, alpha-2A,Adrenergic Receptor, alpha-2B,Adrenergic Receptor, alpha-2C,Adrenergic Receptor, alpha-2D,Adrenergic Receptors, alpha-2,Adrenergic alpha 2 Receptors,Adrenergic alpha 2A Receptors,Adrenergic alpha 2B Receptors,Adrenergic alpha 2C Receptors,Adrenergic alpha 2D Receptors,Receptor alpha-2C, Adrenergic,Receptor alpha-2b, Adrenergic,Receptor, alpha-2 Adrenergic,Receptor, alpha-2A Adrenergic,Receptor, alpha-2B Adrenergic,Receptor, alpha-2C Adrenergic,Receptor, alpha-2D Adrenergic,Receptors, Adrenergic alpha-2,Receptors, Adrenergic alpha-2A,Receptors, Adrenergic alpha-2B,Receptors, Adrenergic alpha-2C,Receptors, Adrenergic alpha-2D,Receptors, alpha 2 Adrenergic,alpha 2A Adrenergic Receptor,alpha 2B Adrenergic Receptor,alpha 2C Adrenergic Receptor,alpha 2D Adrenergic Receptor,alpha-2 Adrenergic Receptor,alpha-2 Receptors, Adrenergic,alpha-2A Receptors, Adrenergic,alpha-2B Receptors, Adrenergic,alpha-2C Receptors, Adrenergic,alpha-2C, Adrenergic Receptor,alpha-2D Receptors, Adrenergic,alpha-2b, Adrenergic Receptor

Related Publications

A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
January 2019, Frontiers in psychiatry,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
April 2022, Biomedicines,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
January 2012, Neuroscience letters,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
July 2007, Behavioral and brain functions : BBF,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
March 2006, American journal of respiratory and critical care medicine,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
August 2011, Pharmacogenomics,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
January 2010, Neuropsychobiology,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
August 2001, Pharmacogenomics,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
March 2001, Molecular psychiatry,
A A Bolonna, and M J Arranz, and J Munro, and S Osborne, and M Petouni, and M Martinez, and R W Kerwin
January 1999, Psychopharmacology,
Copied contents to your clipboard!